51,380 Shares in AbCellera Biologics Inc. (NASDAQ:ABCL) Purchased by State Board of Administration of Florida Retirement System

State Board of Administration of Florida Retirement System purchased a new stake in AbCellera Biologics Inc. (NASDAQ:ABCLGet Rating) during the second quarter, according to its most recent filing with the SEC. The firm purchased 51,380 shares of the company’s stock, valued at approximately $547,000.

A number of other large investors have also bought and sold shares of the business. Worth Asset Management LLC acquired a new stake in shares of AbCellera Biologics during the first quarter worth $25,000. Banque Cantonale Vaudoise acquired a new position in shares of AbCellera Biologics in the second quarter worth approximately $67,000. Nisa Investment Advisors LLC acquired a new position in AbCellera Biologics in the second quarter valued at approximately $85,000. SG Americas Securities LLC acquired a new position in shares of AbCellera Biologics during the second quarter worth approximately $103,000. Finally, Gryphon Financial Partners LLC acquired a new position in shares of AbCellera Biologics during the first quarter worth approximately $102,000. 44.42% of the stock is owned by institutional investors.

AbCellera Biologics Trading Up 0.6 %

Shares of NASDAQ:ABCL opened at $14.16 on Friday. The stock has a fifty day simple moving average of $11.20 and a two-hundred day simple moving average of $10.37. The stock has a market capitalization of $4.05 billion, a price-to-earnings ratio of 17.92 and a beta of -0.54. AbCellera Biologics Inc. has a 12-month low of $5.42 and a 12-month high of $15.90.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on ABCL shares. Credit Suisse Group reduced their price objective on AbCellera Biologics from $40.00 to $34.00 and set an “outperform” rating for the company in a research note on Wednesday, August 10th. Truist Financial assumed coverage on AbCellera Biologics in a report on Wednesday. They set a “buy” rating and a $29.00 price objective on the stock. SVB Leerink increased their price objective on AbCellera Biologics from $13.00 to $20.00 and gave the stock an “outperform” rating in a report on Wednesday, November 9th. Finally, Piper Sandler lowered their price target on AbCellera Biologics from $22.00 to $21.00 in a report on Tuesday, November 1st. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $28.50.

AbCellera Biologics Company Profile

(Get Rating)

AbCellera Biologics Inc develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners.

Read More

Want to see what other hedge funds are holding ABCL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbCellera Biologics Inc. (NASDAQ:ABCLGet Rating).

Institutional Ownership by Quarter for AbCellera Biologics (NASDAQ:ABCL)

Receive News & Ratings for AbCellera Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbCellera Biologics and related companies with MarketBeat.com's FREE daily email newsletter.